The analyst discusses United Health stock, mentioning he previously rated it a buy between 270 and 235. The stock price has since increased to 359. He refers to Fiscal AI, noting the forward P/E ratio is now 22, up from lows of 13-14 earlier in 2025. He mentions that underperformance in 2025 was due to company estimate mistakes regarding the cost to serve their customers. He uses proprietary discounted cash flow valuations, with the model showing an intrinsic value of 449.17 per share. The analysis emphasizes a decade of free cash flow estimates and a weighted average cost of capital with the balance sheet. He still likes the risk reward profile at current market prices.